The IL-1? inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation, according to late-breaking results.
The IL-1? inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation, according to late-breaking results.